Pneumagen raises £8m to accelerate Phase 2 clinical development of Neumifil for the prevention & treatment of viral respiratory tract infectionsNeumifil is being developed for the prevention and treatment of virus induced exacerbations in patients with respiratory diseaseAdvancing Neumifil into a Phase 2b.
/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral.
/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral.
ST ANDREWS, Scotland, Jan. 19, 2022 /PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral